RayKnowChina Research Map
Shortlist0

RecruitingB-cell acute lymphoblastic leukaemiaPhase 2

Registered title, quoted from ClinicalTrials.gov

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06179524, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. Not stated to 25 years; sex: all

    Registered eligibility fields

  2. Bone marrow examination confirmed the diagnosis of B-ALL, and meet one of the following conditions: Relapsed B-ALL:1)Relapse within 12 months of the first remission;2)Recurrence occurring again more than 12 months after the first remission,, relapsed or not responded after first-line/multi-line salvage chemotherapy;3) Experienced two or more bone marrow recurrences; 4) recurrence after autologous or allogeneic hematopoietic stem cell transplantation; Refractory B-ALL:1)failed to achieve complete remission after 2 cycles of standard induction chemotherapy.

    Inclusion criterion 3

    Ph+ALL patients are eligible:1)Relapsed or refractory after receiving at least two Tyrosine kinase inhibitors (TKI) treatments;If Ph+ALL patients with t315i mutation are resistant to first- and second-generation TKIs, in the absence of effective TKI therapy, patients are not required to receive at least two TKIs;2)cannot tolerate TKI treatment;3)Presence of contraindications to TKI therapy.

    Inclusion criterion 4

    Participants who have received HSCT within 3 months before screening or Presence of grade 2 to 4 active graft-versus-host disease (GVHD), and those who have received systemic drug therapy for GVHD within 4 weeks before infusion.

    Exclusion criterion 8

    Received the following anti-tumor therapy before apheresis:1)Received any chemotherapy, targeted therapy, etc. within 4 weeks or at least 5 half-lives (whichever is shorter);2)Radiotherapy within 14 days;3)Intrathecal treatment within 7 days;4) Received a donor lymphocyte transfusion (DLI) within 4 weeks; 5)Received Blinatumomab within 14 days.

    Exclusion criterion 9

    participated in other interventional clinical studies (received active trial drug treatment) within 3 months before screening, or intend to participate in another clinical trial or receive another anti-tumor therapy.

    Exclusion criterion 17

  3. Karnofsky(age≥16 years)performance status≥70 or Lansky(age<16 years)performance status≥50.

    Inclusion criterion 8

  4. Any of the following applies:1)Hepatitis B surface antigen (HBsAg) positive or HBV-DNA quantity is higher than the upper limit of normal value;2)Hepatitis C virus antibody (HCV Ab) is positive and HCV RNA quantification is higher than the upper limit of normal values;3)Positive for human immunodeficiency virus antibody (HIV-Ab);4)EB virus DNA quantification is higher than the upper limit of normal values;5)Cytomegalovirus DNA quantification is higher than the upper limit of normal values.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06179524, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary participation in clinical trial, The Participants or his legal guardian is fully understands this clinical trial and signs the Informed Consent Form (ICF); Willing to follow and be able to complete all trial procedures.
  • Age≤25 years old at the time of screening, regardless of gender.
  • Bone marrow examination confirmed the diagnosis of B-ALL, and meet one of the following conditions: Relapsed B-ALL:1)Relapse within 12 months of the first remission;2)Recurrence occurring again more than 12 months after the first remission,, relapsed or not responded after first-line/multi-line salvage chemotherapy;3) Experienced two or more bone marrow recurrences; 4) recurrence after autologous or allogeneic hematopoietic stem cell transplantation; Refractory B-ALL:1)failed to achieve complete remission after 2 cycles of standard induction chemotherapy.
  • Ph+ALL patients are eligible:1)Relapsed or refractory after receiving at least two Tyrosine kinase inhibitors (TKI) treatments;If Ph+ALL patients with t315i mutation are resistant to first- and second-generation TKIs, in the absence of effective TKI therapy, patients are not required to receive at least two TKIs;2)cannot tolerate TKI treatment;3)Presence of contraindications to TKI therapy.
  • Bone marrow (BM) or peripheral blood (PB) tumor cells were measured to express CD19 at screening.
  • Bone marrow blasts ≥ 5% at screening.
  • Adequate organ function and must meet the following criteria: Alanine aminotransferase (ALT) ≤ 5 ×Upper limit of normal value(ULN);Total serum bilirubin ≤ 2.0 ×ULN((for Gilbert syndrome, total bilirubin≤3.0×ULN);in non-oxygen state, No > grade 1 dyspnea, Blood oxygen saturation > 95%;left ventricular ejection fraction(LVEF) ≥ 50%;Serum creatinine≤1.5 × ULN;
  • Karnofsky(age≥16 years)performance status≥70 or Lansky(age<16 years)performance status≥50.
  • Life expectancy ≥ 12 weeks.
  • Adequate venous access (for apheresis) and no other contraindications to apheresis.
  • Negative blood/urine pregnancy test in women of childbearing potential before screening and within 3 days prior to cell infusion, and any male and female patients of childbearing potential must agree to use an effective method of contraception throughout the study and for at least 2 years after CAR-T-19 infusion. In the judgment of the investigator, a patient of childbearing potential means that he/she is biologically capable of having children and having a normal sexual life.
  • For Participants who have previously undergone allogeneic hematopoietic stem cell transplantation, CAR-T-19 cell preparation is performed using their previous donor peripheral blood, and the donor needs to meet the following conditions:1)Have donated bone marrow/hematopoietic stem cells as a transplant donor for the patient;2)Age ≥8 years at screening;3)Voluntary participation in clinical studies; the donor (and legal guardian, if applicable) am fully aware of and informed about this trial and have signed an informed consent form (ICF); Willing to follow and be able to complete all trial procedures;4)Have adequate venous access (for apheresis or venous blood collection) and no other contraindications to apheresis; 5) The etiological test results do not correspond to any of the exclusion criteria outlined in item 12. 6) Women of childbearing age have negative blood and urine pregnancy tests.7) Systemic glucocorticoid therapy is prohibited within one week prior to apheresis, with the exception of physiologically replacement doses of glucocorticoids (0.5 mg/kg/day of prednisone or equivalent doses of other corticosteroids).8) There are no cases of uncontrolled fungal, bacterial, viral, or other infections requiring intravenous treatment.

Exclusion Criteria:

  • Isolated extra-medullary disease relapse .
  • Participants with genetic syndromes, Patients with Down Syndrome will not be excluded.
  • Participants with Burkitt's lymphoma/leukemia.
  • Participants with active central nervous system disease.
  • Active central nervous system leukemia at screening(Defined as CNS-3 and CNS-2 grades with neurological symptoms as defined by NCCN guidelines and judged by the investigator to be active central leukemia).
  • Participants with a history of other malignant tumors or other malignant tumors at the same time (excluding fully treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, thyroid cancer, ductal carcinoma in situ after radical resection).
  • have or suspected to have fungal, bacterial, viral or other infections that are uncontrollable or require intravenous treatment.
  • Participants who have received HSCT within 3 months before screening or Presence of grade 2 to 4 active graft-versus-host disease (GVHD), and those who have received systemic drug therapy for GVHD within 4 weeks before infusion.
  • Received the following anti-tumor therapy before apheresis:1)Received any chemotherapy, targeted therapy, etc. within 4 weeks or at least 5 half-lives (whichever is shorter);2)Radiotherapy within 14 days;3)Intrathecal treatment within 7 days;4) Received a donor lymphocyte transfusion (DLI) within 4 weeks; 5)Received Blinatumomab within 14 days.
  • Participants who have been treated with systemic glucocorticoids within 1 week before apheresis, physiological replacement doses of steroids are allowed.
  • Long-acting G-CSF is prohibited within 21 days and short-acting G-CSF is prohibited within 7 days before apheresis.
  • Any of the following applies:1)Hepatitis B surface antigen (HBsAg) positive or HBV-DNA quantity is higher than the upper limit of normal value;2)Hepatitis C virus antibody (HCV Ab) is positive and HCV RNA quantification is higher than the upper limit of normal values;3)Positive for human immunodeficiency virus antibody (HIV-Ab);4)EB virus DNA quantification is higher than the upper limit of normal values;5)Cytomegalovirus DNA quantification is higher than the upper limit of normal values.
  • Those who have received CAR-T therapy with any target.
  • Allergy to albumin and aminoglycoside antibiotics.
  • Received live vaccine within 6 weeks before screening.
  • Participants after organ transplantation (except hematopoietic stem cell transplantation).
  • participated in other interventional clinical studies (received active trial drug treatment) within 3 months before screening, or intend to participate in another clinical trial or receive another anti-tumor therapy.
  • Other investigators deem it inappropriate to participate in the study.

Quoted from ClinicalTrials.gov, NCT06179524, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06179524, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06179524